Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04704661
Title Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)

salivary gland cancer

endometrial cancer

stomach cancer

gastroesophageal cancer

colorectal cancer

colon cancer

Advanced Solid Tumor

breast cancer


Ceralasertib + Trastuzumab deruxtecan

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.